Oncimmune (LON:ONC) Sets New 1-Year Low – Here’s What Happened

Shares of Oncimmune Holdings plc (LON:ONC) hit a new 52-week low during trading on Tuesday . The company traded as low as GBX 7.50 ($0.09) and last traded at GBX 7.70 ($0.10), with a volume of 518290 shares trading hands. The stock had previously closed at GBX 8.68 ($0.11).

Oncimmune Price Performance

The company’s fifty day moving average is GBX 13.37 and its two-hundred day moving average is GBX 14.80. The company has a debt-to-equity ratio of 806.85, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a market cap of £5.71 million, a price-to-earnings ratio of -256.67 and a beta of 1.19.

Oncimmune (LON:ONC) last issued its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share for the quarter. Oncimmune had a negative return on equity of 760.96% and a net margin of 586.08%.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.